Spago Nanomedical publishes scientific paper on positive preclinical data with Tumorad® as treatment of solid tumors

Spago Nanomedical AB (publ) today announced the publication of data on the composition, stability, and mode of action for its leading candidate drug 177Lu-SN201.

The preclinical results shows that the candidate drug accumulates favorably in tumors, inhibits tumor growth, provides prolonged survival compared to control, and is suitable for systemic treatment of cancer. The paper was published in the scientific journal ACS Omega.

”The need for more effective methods to treat metastatic and aggressive cancer remains significant. Spago Nanomedical´s candidate drug 177Lu-SN201 belongs to a new generation of targeted radionuclide treatments that provides opportunity for precision treatment of cancer, as monotherapy or in combination with other treatments.